Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.
It is a macrocyclic protein kinase inhibitor.
It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
Routes of administration By mouth
Pacritinib in indicated to treat intermediate or high-risk primary or secondary myelofibrosis and who have platelet levels below 50,000/µL.
The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment.
29% of patients in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to 3% in the standard treatment group.